HK1116500A1 - Antibodies directed against amyloid-beta peptide and methods using same - Google Patents

Antibodies directed against amyloid-beta peptide and methods using same

Info

Publication number
HK1116500A1
HK1116500A1 HK08106860.6A HK08106860A HK1116500A1 HK 1116500 A1 HK1116500 A1 HK 1116500A1 HK 08106860 A HK08106860 A HK 08106860A HK 1116500 A1 HK1116500 A1 HK 1116500A1
Authority
HK
Hong Kong
Prior art keywords
methods
same
directed against
antibodies directed
beta peptide
Prior art date
Application number
HK08106860.6A
Other languages
English (en)
Inventor
Arnon Rosenthal
Jaume Pons
Wei-Hsien Ho
Jan Markus Grimm
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Publication of HK1116500A1 publication Critical patent/HK1116500A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK08106860.6A 2004-07-30 2008-06-20 Antibodies directed against amyloid-beta peptide and methods using same HK1116500A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59249404P 2004-07-30 2004-07-30
US65319705P 2005-02-14 2005-02-14
US67609305P 2005-04-29 2005-04-29
PCT/US2005/027295 WO2006036291A2 (fr) 2004-07-30 2005-08-01 Anticorps anti peptide amyloide beta, et leurs procedes d'utilisation

Publications (1)

Publication Number Publication Date
HK1116500A1 true HK1116500A1 (en) 2008-12-24

Family

ID=36010949

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08106860.6A HK1116500A1 (en) 2004-07-30 2008-06-20 Antibodies directed against amyloid-beta peptide and methods using same

Country Status (21)

Country Link
US (4) US7807165B2 (fr)
EP (2) EP1781704A2 (fr)
JP (2) JP5042828B2 (fr)
KR (2) KR20070040824A (fr)
AP (1) AP2007003890A0 (fr)
AU (2) AU2005290250A1 (fr)
BR (1) BRPI0513959A (fr)
CA (1) CA2575663C (fr)
EA (1) EA016357B1 (fr)
GE (1) GEP20115195B (fr)
HK (1) HK1116500A1 (fr)
IL (1) IL180364A (fr)
MA (1) MA28757B1 (fr)
MX (1) MX2007000998A (fr)
NI (1) NI200700021A (fr)
NO (1) NO20066058L (fr)
NZ (1) NZ552480A (fr)
SG (1) SG190665A1 (fr)
TN (1) TNSN07031A1 (fr)
TW (1) TWI355389B (fr)
WO (1) WO2006036291A2 (fr)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
BR0315157A (pt) * 2002-10-09 2005-08-09 Rinat Neuroscience Corp Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP2006516639A (ja) * 2003-02-01 2006-07-06 ニユーララブ・リミテツド 可溶性Ａ−βに対する抗体を生成させるための能動免疫
GEP20115195B (en) 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
CA2590337C (fr) * 2004-12-15 2017-07-11 Neuralab Limited Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
US7731962B2 (en) * 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
US8420093B2 (en) 2005-02-14 2013-04-16 Merck Sharp & Dohme Corp. Anti-ADDL monoclonal antibody and use thereof
PE20061323A1 (es) * 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
KR20150098683A (ko) * 2005-12-12 2015-08-28 에이씨 이뮨 에스.에이. 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
SG173385A1 (en) 2006-07-14 2011-08-29 Ac Immune S A Ch Humanized antibody against amyloid beta
WO2008030251A1 (fr) * 2006-09-08 2008-03-13 Georgetown University Anticorps deglycosylés anti-bêta amyloïde
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (fr) * 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Méthode de traitement d'amyloïdoses
EP2117540A1 (fr) 2007-03-01 2009-11-18 Probiodrug AG Nouvelle utilisation d'inhibiteurs de la glutaminyl cyclase
US20090022728A1 (en) * 2007-03-09 2009-01-22 Rinat Neuroscience Corporation Methods of treating ophthalmic diseases
MX2009011127A (es) * 2007-04-18 2010-03-10 Janssen Alzheimer Immunotherap Metodo de prevencion y tratamiento de angiopatia amiloide cerebral.
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8323654B2 (en) * 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
RU2567151C2 (ru) * 2007-06-12 2015-11-10 Ац Иммуне С.А. Гуманизированные антитела к амилоиду бета
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
CL2008001742A1 (es) * 2007-06-12 2008-11-21 Ac Immune Sa Anticuerpo monoclonal que reconoce un epitope conformacional y se une a peptidos amiloides solubles polimericos y peptidos amiloides oligomericos; polinucleotido que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados a proteinas amiloides.
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
CA2704064A1 (fr) 2007-09-13 2009-03-29 University Of Zurich Anticorps humanises contre le peptide beta-amyloide
EP2527369A3 (fr) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Anticorps monoclonal anti-bêta-amyloide (abêta) et ses utilisations
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
SG185277A1 (en) * 2007-10-05 2012-11-29 Genentech Inc Humanized antibody
AU2008311367B2 (en) 2007-10-05 2014-11-13 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
AU2008312611A1 (en) * 2007-10-15 2009-04-23 Centocor, Inc. Human anti-amyloid antibodies, compositions, methods and uses
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
PL2250279T3 (pl) 2008-02-08 2016-11-30 Przeciwciała anty-ifnar1 o zmniejszonym powinowactwie do liganda fc
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8614297B2 (en) 2008-12-22 2013-12-24 Hoffmann-La Roche Inc. Anti-idiotype antibody against an antibody against the amyloid β peptide
WO2010088411A2 (fr) 2009-01-30 2010-08-05 Adlyfe, Inc. Peptides dynamiques par conformation
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
DK2448968T3 (da) * 2009-06-29 2021-04-12 Bioarctic Ab ANTISTOFFER SOM ER SELEKTIVE FOR N-TERMINAL-TRUNKEREDE AMYLOID-ß PROTOFIBRILLER/OLIGOMERER
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
CN103140500B (zh) * 2010-07-14 2015-09-09 默沙东公司 抗addl单克隆抗体及其用途
US9320793B2 (en) 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
US9176151B2 (en) 2010-07-14 2015-11-03 Acumen Pharmaceuticals, Inc. Antibodies, kit and method for detecting amyloid beta oligomers
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
CN103068848B (zh) * 2010-08-12 2015-11-25 伊莱利利公司 抗N3pGlu淀粉样蛋白BETA肽抗体及其用途
EP2603524A1 (fr) 2010-08-14 2013-06-19 AbbVie Inc. Protéines de liaison bêta-amyloïdes
LT2648752T (lt) 2010-12-06 2017-04-10 Seattle Genetics, Inc. Humanizuoti antikūnai prieš liv-1 ir jų panaudojimas vėžio gydymui
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
CA2830027C (fr) 2011-03-31 2016-04-26 Pfizer Inc. Nouvelles pyridones bicycliques
WO2012172449A1 (fr) 2011-06-13 2012-12-20 Pfizer Inc. Lactames convenant comme inhibiteurs des bêta-sécrétases
BR112013032630B1 (pt) 2011-06-30 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Polipeptídeo heterodimerizado compreendendo região fc de igg
ES2605565T3 (es) 2011-08-31 2017-03-15 Pfizer Inc Compuestos de hexahidropirano [3,4-D][1,3]tiazin-2-amina
KR20160005380A (ko) * 2011-09-23 2016-01-15 에이씨 이뮨 에스.에이. 백신 요법
WO2013106572A1 (fr) 2012-01-11 2013-07-18 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Fragments d'anticorps bispécifiques pour protéines associées à une maladie neurologique, et procédés d'utilisation
ES2585262T3 (es) 2012-05-04 2016-10-04 Pfizer Inc Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
JP6628966B2 (ja) 2012-06-14 2020-01-15 中外製薬株式会社 改変されたＦｃ領域を含む抗原結合分子
EP2867236B1 (fr) 2012-06-29 2017-06-14 Pfizer Inc Nouvelles 7h-pyrrolo[2,3-d]pyrimidines substituées par un groupe amino en position 4, utilisées comme inhibiteurs de lrrk2
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
EP2897964A1 (fr) 2012-09-20 2015-07-29 Pfizer Inc. Composés de hexahydropyrano [3,4-d][1,3]thiazin-2-amine substitués par alkyle
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
CA2893256A1 (fr) 2012-12-11 2014-06-19 Pfizer Inc. Composes d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
WO2014097038A1 (fr) 2012-12-19 2014-06-26 Pfizer Inc. Composés hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués carbocycliques et hétérocycliques
CA2893977C (fr) 2012-12-21 2024-02-13 Seattle Genetics, Inc. Anticorps anti-ntb-a et compositions et procedes associes
US10766960B2 (en) 2012-12-27 2020-09-08 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
WO2014125394A1 (fr) 2013-02-13 2014-08-21 Pfizer Inc. Composés hexahydropyrano [3,4-d][1,3] thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
PE20151332A1 (es) 2013-02-19 2015-09-20 Pfizer Compuestos de azabencimidazol
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
KR20140128230A (ko) 2013-04-26 2014-11-05 한국과학기술연구원 혈액 중 단백질 응집체의 용해를 통한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 진단키트
PE20151926A1 (es) 2013-05-20 2016-01-07 Genentech Inc Anticuerpos de receptores de antitransferrina y metodos de uso
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
ES2742078T3 (es) 2013-10-04 2020-02-13 Pfizer Piridonas bicíclicas novedosas como moduladores de gamma-secretasa
CA2933767C (fr) 2013-12-17 2018-11-06 Pfizer Inc. Nouvelles 1h-pyrrolo[2,3- b]pyridines 3,4-disubstituees et 7h-pyrrolo[2,3-c]pyridazines 4,5-disubstituees en tant qu'inhibiteurs de la lrrk2
ES2759277T3 (es) 2014-04-01 2020-05-08 Pfizer Cromeno y 1,1a,2,7b-tetrahidrociclopropa[c]cromeno piridopiracinadionionas como moduladores de gamma-secretasa
AP2016009493A0 (en) 2014-04-10 2016-10-31 Pfizer 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
KR102061952B1 (ko) 2014-08-06 2020-01-02 화이자 인코포레이티드 이미다조피리다진 화합물
EP3221362B1 (fr) 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anticorps anti-récepteur de transferrine et procédés d'utilisation
EP3221361B1 (fr) 2014-11-19 2021-04-21 Genentech, Inc. Anticorps multispécifiques anti-récepteur de transferrine / anti-bace1 et procédés d'utilisation
CN107250157B (zh) 2014-11-21 2021-06-29 百时美施贵宝公司 包含修饰的重链恒定区的抗体
ME03806B (fr) 2014-11-21 2021-04-20 Bristol Myers Squibb Co Anticorps anti-cd73 et leurs utilisations
MX2017007491A (es) 2014-12-10 2018-05-04 Genentech Inc Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso.
EP3253755B1 (fr) 2015-02-03 2020-08-26 Pfizer Inc Nouveaux pyridopyrazinediones cyclopropabenzofuranyl
KR102426986B1 (ko) 2015-06-17 2022-07-28 화이자 인코포레이티드 삼환형 화합물 및 포스포다이에스터라제 억제제로서 이의 용도
EP4302784A3 (fr) 2015-06-30 2024-03-13 Seagen Inc. Anticorps anti-ntb-a ainsi que compositions et procédés associés
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
EP3353183A1 (fr) 2015-09-24 2018-08-01 Pfizer Inc N-[2-(2-amino-6,6-disubstitués-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl)-1,3-thiazol-4-yl]amides
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
WO2017079369A2 (fr) * 2015-11-03 2017-05-11 Glaxosmithkline Llc Nouveaux anticorps
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
CA3011900A1 (fr) 2016-02-17 2017-08-24 Seattle Genetics, Inc. Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques
KR102148587B1 (ko) 2016-02-23 2020-08-26 화이자 인코포레이티드 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물
EP3872078A1 (fr) 2016-07-01 2021-09-01 Pfizer Inc. Dérivés de 5,7-dihydro-pyrrolo-pyridine destinés à être utilisés dans le traitement de la dépression, l'angoisse et les troubles paniques
TWI798751B (zh) 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
US11312713B2 (en) 2017-03-10 2022-04-26 Pfizer Inc. Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors
WO2018163030A1 (fr) 2017-03-10 2018-09-13 Pfizer Inc. Dérivés d'imidazo [4,5-c] quinoléine substitués cycliques
CN110650976B (zh) 2017-04-13 2024-04-19 赛罗帕私人有限公司 抗SIRPα抗体
JOP20190247A1 (ar) 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
BR112019022873A8 (pt) 2017-05-02 2023-04-11 Merck Sharp & Dohme Formulação, e, vaso ou dispositivo de injeção.
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3634978A1 (fr) 2017-06-07 2020-04-15 Adrx, Inc. Inhibiteur d'agrégation de tau
MX2019015371A (es) 2017-06-22 2020-07-20 Pfizer Derivados de dihidro-pirrolo-piridina.
CA3067597C (fr) 2017-06-29 2023-03-21 The Trustees Of Columbia University In The City Of New York Anticorps chimeriques pour le traitement de maladies de depot amyloide
EP3431496A1 (fr) * 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anticorps amyloïdes beta anti-isoasp7 et leurs utilisations
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
CA3073062A1 (fr) 2017-08-18 2019-02-21 Adrx, Inc. Inhibiteurs peptidiques d'agregation de tau
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
EP3508499A1 (fr) 2018-01-08 2019-07-10 iOmx Therapeutics AG Anticorps ciblant et d'autres modulateurs d'un gène d'immunoglobuline associé à une résistance contre des réponses immunitaires antitumorales et leurs utilisations
WO2019148412A1 (fr) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anticorps bispécifiques anti-pd-1/lag3
CA3094366A1 (fr) 2018-03-23 2019-09-26 Pfizer Inc. Derives azaspiro de piperazine
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
CN112638944A (zh) 2018-08-23 2021-04-09 西进公司 抗tigit抗体
CA3115071A1 (fr) 2018-10-04 2020-04-09 University Of Rochester Amelioration de l'administration glymphatique par manipulation de l'osmolarite du plasma
JP2022514290A (ja) 2018-12-20 2022-02-10 ジェネンテック， インコーポレイテッド 改変抗体ｆｃおよび使用方法
JP2022519273A (ja) 2019-02-05 2022-03-22 シージェン インコーポレイテッド 抗ｃｄ２２８抗体及び抗体薬物コンジュゲート
EP3994171A1 (fr) 2019-07-05 2022-05-11 iOmx Therapeutics AG Anticorps de liant à l'igc2 de l'igsf11 (vsig3) et leurs utilisations
WO2021067776A2 (fr) 2019-10-04 2021-04-08 Seagen Inc. Anticorps anti-pd-l1 et conjugués anticorps-médicament
EP3822288A1 (fr) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Anticorps ciblant et autres modulateurs de l'antigène cd276 et leurs utilisations
KR20230005163A (ko) 2020-03-26 2023-01-09 씨젠 인크. 다발성 골수종 치료 방법
CN111334480B (zh) * 2020-05-18 2020-09-01 苏州仁端生物医药科技有限公司 一种分泌抗Aβ1-42单克隆抗体的杂交瘤细胞株及其应用
EP4175668A1 (fr) 2020-07-06 2023-05-10 iOmx Therapeutics AG Anticorps de liaison à l'igv d'igsf11 (vsig3) et leurs utilisations
EP4185612A1 (fr) 2020-07-23 2023-05-31 Othair Prothena Limited Anticorps anti-abêta
KR20230042518A (ko) 2020-08-04 2023-03-28 씨젠 인크. 항-cd228 항체 및 항체-약물 컨쥬게이트
JP2023547507A (ja) 2020-11-03 2023-11-10 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ 標的細胞限定的で共刺激性の二重特異性かつ２価の抗ｃｄ２８抗体
KR20230104659A (ko) 2020-11-08 2023-07-10 씨젠 인크. 면역 세포 억제제를 이용한 조합-요법 항체 약물 접합체
CA3203308A1 (fr) 2020-11-30 2022-06-02 Enigma Biointelligence, Inc. Evaluation non invasive de la maladie d'alzheimer
WO2022162203A1 (fr) 2021-01-28 2022-08-04 Vaccinvent Gmbh Méthodes et moyens pour moduler des réponses immunitaires à médiation par des lymphocytes b
CN117120084A (zh) 2021-01-28 2023-11-24 维肯芬特有限责任公司 用于调节b细胞介导的免疫应答的方法和手段
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
AU2022254727A1 (en) 2021-04-09 2023-10-12 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
WO2022251048A1 (fr) 2021-05-24 2022-12-01 Eli Lilly And Company Anticorps anti-amyloïde bêta et leurs utilisations
TW202327650A (zh) 2021-09-23 2023-07-16 美商思進公司 治療多發性骨髓瘤之方法
WO2024068777A1 (fr) 2022-09-28 2024-04-04 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Protéines ace2 modifiées présentant une activité améliorée contre le sars-cov-2
WO2024086796A1 (fr) 2022-10-20 2024-04-25 Alector Llc Anticorps anti-ms4a4a avec des thérapies à base d'amyloïdes-bêta
WO2024097816A1 (fr) 2022-11-03 2024-05-10 Seagen Inc. Anticorps anti-avb6 et conjugués anticorps-médicaments et leur utilisation dans le traitement du cancer
WO2024108053A1 (fr) 2022-11-17 2024-05-23 Sanofi Conjugués anticorps-médicaments de ceacam5 et leurs méthodes d'utilisation
WO2024133940A2 (fr) 2022-12-23 2024-06-27 Iomx Therapeutics Ag Protéines de liaison à un antigène (abp) inter-spécifiques ciblant une sous-famille b1 de récepteur de type immunoglobuline leucocytaire (lilrb1) et lilrb2, combinaisons et utilisations associées
WO2024191807A1 (fr) 2023-03-10 2024-09-19 Seagen Inc. Méthodes de traitement du cancer à l'aide d'anticorps anti-tigit

Family Cites Families (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3143171A (en) * 1961-04-11 1964-08-04 Shell Oil Co Underwater well guide system
US3787637A (en) * 1971-07-26 1974-01-22 Audichron Co Announcing system
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4403112A (en) 1981-05-18 1983-09-06 Modafferi Acoustical Systems, Ltd. Phase shift low frequency loudspeaker system
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4891268A (en) 1984-03-26 1990-01-02 Metal Coatings International Inc. Coated metal substrates with anticorrosion coating composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
GB8516081D0 (en) 1985-06-25 1985-07-31 Ciba Geigy Ag Assay & purification of amyloid components
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5231170A (en) 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5525339A (en) 1986-08-27 1996-06-11 Dms Pharmaceutical Inc. Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
CA1339014C (fr) 1987-10-08 1997-03-25 Ronald E. Majocha Anticorps pour peptide a4-amyloide
US5231000A (en) 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990007936A1 (fr) 1989-01-23 1990-07-26 Chiron Corporation Therapies de recombinaison pour infections et troubles hyperproliferatifs
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5262332A (en) 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US5234814A (en) 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
EP1645635A3 (fr) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Retrovirus recombinants défectifs pour la réplication exprimant un palliatif
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
CA2079880A1 (fr) 1990-04-24 1991-10-25 William E. Van Nostrand Purification, detection et mode d'utilisation de la protease nexine-2
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
US5164295A (en) 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
WO1992022653A1 (fr) 1991-06-14 1992-12-23 Genentech, Inc. Procede de production d'anticorps humanises
GB9114324D0 (en) 1991-07-03 1991-08-21 Kontor Moulding Systems Ltd Injection moulding of thermoplastic polymers
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
CA2078539C (fr) 1991-09-18 2005-08-02 Kenya Shitara Procede de fabrication de chimere d'anticorps humain
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993010218A1 (fr) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vecteurs comprenant des genes etrangers et des marqueurs selectifs negatifs
WO1993010260A1 (fr) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Utilisation de la neuraminidase extracellulaire pour lutter contre la degradation d'oligosaccharides de la glycoproteine
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5851787A (en) 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
TW327194B (en) 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
EP0644946A4 (fr) 1992-06-10 1997-03-12 Us Health Particules vecteurs resistantes a l'inactivation par le serum humain.
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
WO1994004690A1 (fr) 1992-08-17 1994-03-03 Genentech, Inc. Immunoadhesines bispecifiques
US5962463A (en) 1992-10-09 1999-10-05 Massachusetts Institute Of Technology Methods of stimulating non-amyloidogenic processing of the amyloid precursor protein
WO1994009370A1 (fr) 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Liberation d'un precurseur amyloide de la maladie d'alzheimer, stimulee par activation des recepteurs d'acetylcholine muscarinique
WO1994009371A1 (fr) 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Test diagnostique ante mortem pour la detection de la maladie d'alzheimer
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
WO1994012649A2 (fr) 1992-12-03 1994-06-09 Genzyme Corporation Therapie genique de la fibrose kystique
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
CA2115900A1 (fr) 1993-02-22 1994-08-23 Gerald W. Becker Cribles pharmaceutiques et anticorps
DK0695169T3 (da) 1993-04-22 2003-03-17 Skyepharma Inc Multivesikulære liposomer med indkapslet cyclodextrin og farmakologisk aktive forbindelser samt fremgangsmåder til anvendelse af disse
US6107050A (en) 1993-05-03 2000-08-22 The United States Of America As Represented By The Department Of Health And Human Services Diagnostic test for alzheimers disease
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
CA2166118C (fr) 1993-06-24 2007-04-17 Frank L. Graham Vecteurs d'adenovirus pour therapie genique
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DE69435224D1 (de) 1993-09-15 2009-09-10 Novartis Vaccines & Diagnostic Rekombinante Alphavirus-Vektoren
CA2174501A1 (fr) 1993-10-20 1995-04-27 Warren J. Strittmatter Procede de liaison d'un element au peptide .beta.-amylo?de
PT797676E (pt) 1993-10-25 2006-05-31 Canji Inc Vector adenoviral recombinante e metodos de utilizacao
RU2160093C2 (ru) 1993-11-16 2000-12-10 Скайефарма Инк. Везикулы с регулируемым высвобождением активных ингредиентов
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
CA2158977A1 (fr) 1994-05-09 1995-11-10 James G. Respess Vecteurs retroviraux a taux de recombinaison reduit
US5525126A (en) 1994-10-31 1996-06-11 Agricultural Utilization Research Institute Process for production of esters for use as a diesel fuel substitute using a non-alkaline catalyst
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5804560A (en) 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
AU6383396A (en) 1995-06-07 1996-12-30 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
US6221645B1 (en) 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
US5958684A (en) 1995-10-02 1999-09-28 Van Leeuwen; Frederik Willem Diagnosis of neurodegenerative disease
WO1997042338A1 (fr) 1996-05-06 1997-11-13 Chiron Corporation Vecteurs retroviraux sans croisement
US6107029A (en) 1996-07-31 2000-08-22 Message Pharmaceticals, Inc. Universal method for detecting interactions between RNA molecules and RNA binding proteins
CA2279651A1 (fr) 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions et procedes de traitement de troubles neurologiques et de maladies neurodegeneratives
US5976817A (en) 1996-10-31 1999-11-02 Trustees Of Boston University Diagnostic method for detecting Alzheimer's disease in living patients
US20030068316A1 (en) 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6221670B1 (en) 1997-03-21 2001-04-24 Scios Inc. Methods to identify β-amyloid reducing agents
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US20020086847A1 (en) 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
WO1999018792A1 (fr) 1997-10-10 1999-04-22 Johns Hopkins University Compositions et procedes d'apport de genes
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
GB9809951D0 (en) * 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
EP1002862A1 (fr) 1998-11-12 2000-05-24 Nitsch, Roger M., Prof. Dr. Procédés pour diagnostiquer ou traiter des maladies neurologiques
US6143171A (en) 1999-04-07 2000-11-07 Van Aarsen; Freda Martha Magnetic device for treatment of fluids
ATE355527T1 (de) 1999-05-03 2006-03-15 Evotec Ag Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
DK1409654T3 (da) 1999-06-16 2008-12-08 Boston Biomedical Res Inst Immunologisk styring af beta-amyloid-niveauer in vivo
US6255054B1 (en) 1999-09-09 2001-07-03 Jacques Hugon Polymorphism of the human GluR-5 gene and risk factor for alzheimer disease
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
CA2404237C (fr) 2000-04-05 2010-01-26 University Of Tennessee Research Corporation Techniques d'etude, de diagnostic et de traitement d'amylose
EP1172378A1 (fr) 2000-07-12 2002-01-16 Richard Dr. Dodel Anticorps humains anti-beta-amyloid et leur utilisation pour le traitement de la maladie d'Alzheimer
US20020009445A1 (en) 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US20040038302A1 (en) 2000-09-19 2004-02-26 Roger Nitsch Methods and compounds for treating brain amyloidosis
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
EP1421607A2 (fr) 2001-02-12 2004-05-26 ASM America, Inc. Procede ameliore permettant de deposer des films semi-conducteurs
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
US6573276B2 (en) 2001-05-09 2003-06-03 Boehringer Ingelheim Pharma Kg Muscarinic M1 agonist as an inhibitor of beta-amyloid (Aβ40 and Aβ42)-synthesis
AU2002345843A1 (en) 2001-06-22 2003-01-08 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
EP1429805A4 (fr) 2001-08-17 2005-09-21 Lilly Co Eli Utilisation d'anticorps ayant une forte affinite pour le peptide a$g(b) dans le traitement de pathologies et de maladies liees a a$g(b)
JP2005508171A (ja) 2001-11-02 2005-03-31 タノックス インコーポレーテッド Ｂ細胞悪性病変の診断及び予防に用いるためのｂ細胞リンパ腫特異抗原
EP1448601A4 (fr) 2001-11-02 2006-04-26 Diagenics Internat Corp Methodes et compositions d'anticorps monoclonaux specifiques des proteines beta-amyloides
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003226356A1 (en) * 2002-04-12 2003-10-27 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
WO2003090772A1 (fr) 2002-04-25 2003-11-06 Eli Lilly And Company Procede pour traiter l'anxiete et les troubles de l'humeur chez des sujets ages
EP1535075A2 (fr) 2002-06-20 2005-06-01 Axonyx, Inc. Methode de dosage
AUPS306402A0 (en) 2002-06-20 2002-07-11 Aguilar, Marie-Isabel Assay method
WO2004024090A2 (fr) 2002-09-12 2004-03-25 The Regents Of The University Of California Immunogenes et anticorps correspondant specifiques pour des intermediaires d'agregation de poids moleculaire eleve communs a des amyloides constitues par des proteines de sequences differentes
ES2201929B1 (es) 2002-09-12 2005-05-16 Araclon Biotech, S.L. Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
WO2004029629A1 (fr) 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. Anticorps monoclonaux beta-amyloide n-11 tronques, compositions, methodes et utilisations
BR0315157A (pt) 2002-10-09 2005-08-09 Rinat Neuroscience Corp Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
AU2003303198A1 (en) 2002-12-19 2004-07-14 New York University Method for treating amyloid disease
EP1575517B1 (fr) 2002-12-24 2012-04-11 Rinat Neuroscience Corp. Anticorps anti-ngf et procedes d'utilisation de ces anticorps
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
WO2005028511A2 (fr) 2003-03-28 2005-03-31 Centocor, Inc. Anticorps anti-amyloides, compositions, procedes et utilisations
AU2003276107A1 (en) 2003-04-24 2004-11-19 Universitat Zurich Method of monitoring immunotherapy
ES2246177B1 (es) 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
WO2005011599A2 (fr) 2003-08-01 2005-02-10 Northwestern University Anticorps specifiques des oligomeres a proteines beta amyloides toxiques
WO2005018424A2 (fr) 2003-08-18 2005-03-03 Research Foundation For Mental Hygiene, Inc. Anticorps specifiques de la proteine amyloide fibrillaire et procedure permettant de detecter des depots de proteines amyloides fibrillaires
CA2538220A1 (fr) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Utilisation d'un anticorps
JP2007527865A (ja) 2003-09-12 2007-10-04 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 種々の配列を有するタンパク質から形成されたアミロイドに共通の高分子量凝集中間体に特異的なモノクローナル抗体
EP1766396B1 (fr) * 2004-06-07 2010-08-11 Ramot at Tel-Aviv University Ltd. Procede d'immunisation passive contre des maladies ou des troubles caracterise(e)s par agregation amyloide a risque diminue de neuroinflammation
GEP20115195B (en) 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
CL2008001742A1 (es) 2007-06-12 2008-11-21 Ac Immune Sa Anticuerpo monoclonal que reconoce un epitope conformacional y se une a peptidos amiloides solubles polimericos y peptidos amiloides oligomericos; polinucleotido que lo codifica; composicion que lo comprende; y su uso para tratar enfermedades asociados a proteinas amiloides.

Also Published As

Publication number Publication date
EA016357B1 (ru) 2012-04-30
CA2575663C (fr) 2013-04-23
US8425905B2 (en) 2013-04-23
IL180364A0 (en) 2007-06-03
WO2006036291A3 (fr) 2006-07-20
US20060057702A1 (en) 2006-03-16
US8268593B2 (en) 2012-09-18
KR20070040824A (ko) 2007-04-17
GEP20115195B (en) 2011-04-11
TNSN07031A1 (fr) 2008-06-02
EP2298807A3 (fr) 2011-05-18
TWI355389B (en) 2012-01-01
NZ552480A (en) 2010-01-29
AU2010200115B2 (en) 2012-05-17
US7807165B2 (en) 2010-10-05
SG190665A1 (en) 2013-06-28
US7927594B2 (en) 2011-04-19
NI200700021A (es) 2008-01-22
TW200617023A (en) 2006-06-01
JP2012197292A (ja) 2012-10-18
JP5042828B2 (ja) 2012-10-03
AU2010200115A1 (en) 2010-01-28
JP2008511291A (ja) 2008-04-17
KR20090046974A (ko) 2009-05-11
AP2007003890A0 (en) 2007-02-28
AU2005290250A1 (en) 2006-04-06
MX2007000998A (es) 2007-07-11
WO2006036291A2 (fr) 2006-04-06
EA200700083A1 (ru) 2008-02-28
KR101068289B1 (ko) 2011-09-28
EP2298807A2 (fr) 2011-03-23
IL180364A (en) 2015-10-29
US20120269805A1 (en) 2012-10-25
NO20066058L (no) 2007-01-22
EP1781704A2 (fr) 2007-05-09
CA2575663A1 (fr) 2006-04-06
MA28757B1 (fr) 2007-07-02
BRPI0513959A (pt) 2008-05-20
US20060057701A1 (en) 2006-03-16
US20110008834A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
HK1116500A1 (en) Antibodies directed against amyloid-beta peptide and methods using same
AP2007004217A0 (en) Antibodies directed against amyloid-beta peptide and methods using same
ZA200803484B (en) Antagonist antibodies directed against calcitonin generelated peptide and methods using same
IL191820A0 (en) Anti-ox40l antibodies and methods using same
IL182554A0 (en) Anti-addl antibodies and uses thereof
IL178356A0 (en) Dr5 antibodies and uses thereof
EP1915177A4 (fr) Anticorps d'alpha-synucléine et techniques associées
ZA200805741B (en) Anti-MN antibodies and methods of using same
IL194787A0 (en) Anti-dll4 antibodies and methods using same
HK1190727A1 (zh) 抗體及其使用方法
IL179140A0 (en) Antibody drug conjuates and methods
ZA200608100B (en) IRTA-5 antibodies and their uses
HK1095841A1 (en) M-csf-specific monoclonal antibody and uses thereof m-csf-
IL174304A0 (en) Kid3 and kid3 antibodies that bind thereto
IL176485A0 (en) Agonist anti-trkc antibodies and methods using same
ZA200703406B (en) Anti-ADDL antibodies and uses thereof
SG122903A1 (en) Therapeutic peptides and method
ZA200809100B (en) Anti-DLL4 antibodies and methods using same
ZA200709089B (en) Antibodies directed against amyloid-beta peptide and methods using same
IL180649A (en) Antiproliferative peptides and antibodies for their detection
ZA200607192B (en) Amylin family peptides and methods for making and using them
ZA200702281B (en) IRTA-4 antibodies and their uses
EP1881843A4 (fr) Kinase peptides et anticorps
GB0503093D0 (en) Ricin-binding peptide and methods for use thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180801